UNSPSC 51111824: Exemestane

This classification denotes a steroidal aromatase inhibitor with the molecular formula C20H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NY22HMQ4BX, chemically known as 6-methyleneandrosta-1,4-diene-3,17-dione but generally known as exemestane, which bears US NIH Compound Identifier 60198. European Medicines Agency schedules Exemestane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07492MIG.

UNSPSC 51111824 Exemestane is a Commodity code that covers procurement of this aromatase inhibitor medication, used primarily in hormone receptor-positive breast cancer treatment. State and local governments purchase exemestane through health departments, corrections departments, public hospitals, and integrated health systems to supply inpatient oncology units, outpatient infusion centers, and institutional pharmacy programs. The drug is typically procured as a generic pharmaceutical in tablet form through competitive bidding or cooperative purchasing agreements, often bundled with other oncology therapeutics in broader pharmacy supply contracts. School districts and transit authorities do not typically solicit under this code.

The source provided contains no recent state or local contract opportunities tagged to UNSPSC 51111824. Without posted RFPs, RFQs, IFBs, or ITBs naming exemestane procurement, geographic concentration and issuing-body activity patterns cannot be characterized from current market signals. Firms pursuing exemestane supply contracts to state and local health systems should monitor solicitations from individual state health departments, county hospital systems, and municipal public health agencies; exemestane procurement frequently appears as line items within broader pharmacy supply RFPs rather than as standalone drug solicitations.